Please login to the form below

Not currently logged in

Amgen’s Anna Richo joins UCB as executive VP and general counsel

Meanwhile, Cynthia Patton takes over as Amgen’s senior VP and chief compliance officer

Anna Richo UCBAnna Richo will leave Amgen to join UCB as the Belgian biopharma company's new executive VP and general counsel.

Richo (pictured) is currently senior VP and chief compliance officer at Amgen, a role that will be taken over by Cynthia Patton from October 22.

In her new position at UCB, Richo will become a member of the company's executive committee and report directly to the CEO Roch Doliveux. She succeeds Bob Trainor, who retires at the end of the year after six years in the role.

"I am very happy to welcome Anna's wealth of legal and leadership qualities, which will be a great natural fit with the global teams Bob has led, as well as with UCB's ongoing journey to becoming the patient-centric global biopharma leader," said Doliveux.

"At the same time it is with immense appreciation and regret that we say goodbye to Bob, who has been instrumental in driving UCB's transformation."

Richo has been in her current position since 2008, having spent the previous five years serving as VP law, responsible for managing the company's corporate litigation and law department operations.

Prior to joining Amgen, she spent 12 years at Baxter Healthcare where she held several law-related positions, eventually becoming VP law for Baxter BioScience.

Her replacement at Amgen, Patton, is promoted from a role as VP in the company's law department, with responsibility for commercial legal activities in the US.

Previously, Patton served as the lead commercial lawyer for both Amgen's oncology and inflammation business units.

17th October 2012

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...